Entry Point Capital, LLC Regenxbio Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 12,538 shares of RGNX stock, worth $91,527. This represents 0.04% of its overall portfolio holdings.
Number of Shares
12,538Holding current value
$91,527% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding RGNX
# of Institutions
190Shares Held
44.2MCall Options Held
159KPut Options Held
40.7K-
Black Rock Inc. New York, NY8.61MShares$62.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.79MShares$35 Million2.9% of portfolio
-
Jpmorgan Chase & CO New York, NY4.14MShares$30.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.99MShares$21.8 Million0.0% of portfolio
-
State Street Corp Boston, MA2.19MShares$16 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $316M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...